How to treat rectal neuroendocrine tumor G1

The treatment of rectal neuroendocrine tumor G1 includes endoscopic resection, surgical treatment, radiotherapy and drug treatment. The specific treatment plan should comprehensively consider factors such as tumor size, location, patient age and health status. The treatment methods of rectal neuroendocrine tumor G1 mainly include endoscopic resection, surgical treatment, radiotherapy and drug treatment, etc. The specific treatment plan should be considered comprehensively according to the size, location, age and health status of the tumor. For smaller rectal neuroendocrine tumors G1 Endoscopic resection is a common treatment for tumors (diameter ≤ 10 mm) confined to the mucosal layer. Endoscopic resection includes endoscopic mucosal resection (EMR) and endoscopic mucosal dissection (ESD). These methods can remove tumors endoscopically with less trauma and faster postoperative recovery. 2. Surgical treatment: For larger rectal neuroendocrine tumors G1 Surgery may be a better choice for patients with tumor invasion of submucosa or lymph node metastasis (diameter> 10 mm). Surgical methods include local resection of rectum, radical resection of rectal cancer, etc. Surgery can completely remove the tumor and reduce the risk of recurrence and metastasis. 3. Radiotherapy: Radiotherapy can be used for the treatment of locally advanced or recurrent rectal neuroendocrine tumor G1. Radiotherapy can kill tumor cells by radiation and control tumor growth. 4. Drug therapy: Drug therapy is mainly used for the treatment of advanced or metastatic rectal neuroendocrine tumor G1. Commonly used drugs include somatostatin analogs, targeted drugs, etc. These drugs can alleviate symptoms and prolong survival by inhibiting tumor cell growth and secretion. It should be noted that treatment of rectal neuroendocrine tumor G1 requires a combination of factors, including tumor characteristics, patient health status and treatment objectives. During the treatment process, patients should closely cooperate with the doctor's treatment plan, regular review and follow-up, in order to detect and deal with possible problems in a timely manner. In addition, for high-risk groups, such as familial multiple endocrine adenomatosis patients, long-term treatment of somatostatin analogues patients, etc., should be regularly screened for rectal neuroendocrine tumors, in order to early detection and treatment of tumors. In summary, there are many treatments for rectal neuroendocrine tumor G1, and the treatment effect depends on many factors. Patients should choose the appropriate treatment plan according to their own situation under the guidance of their doctor.